Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

HIV Seropositive Clinical Trial

Official title: Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

Status Completed

Clinical Trial Summary

The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets):

1. Calcium

2. Calcium and 25-hydroxy-vitamin D

3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D

The endpoints are:

• Serum vitamin D

• Parathyroid hormone

• ionized calcium

• T-lymphocyte fractions (naïve, mature, Tregs)

• Osteocalcin (bone metabolism)

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Seropositive
• HIV Seropositivity

• NCT number: NCT00990678
• Study type: Interventional
• Source: Hvidovre University Hospital
• Status: Completed
• Phase: N/A
• Start date: April 2008
• Completion date: January 2011